Body Weight Response With Disulfiram in Humans

• Status: Enrolling by invitation
• Trial end date: 2022-04-30
• Target enrollment: 0
• Participant gender: All

Summary

Overweight and obesity due to food that exceeds the requirements is an increasingly common global problem. Lifestyle intervention and anorectic drugs result in minimal weight loss, which tends to be easily regained. In addition, drugs tend to have too many side effects and have had to be withdrawn from management schemes and even from the market. Disulfiram (Antabuse®️) is approved by the Food and Drug Administration against chronic alcohol addiction. In a mouse study, disulfiram prevented body weight gain and negated the adverse impact of an obesogenic diet on insulin; used properly it is a safe drug. Carrying out a testing-concept study with disulfiram will allow the establishment of guidelines on clinical studies focused on its use as an adjunct in the reduction and control of body weight.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Universidad de Guanajuato
• Collaborator: Laboratorios Doctor Macías
• Treatments: Disulfiram

Criteria

Inclusion Criteria:

• Adults

• 18 to 65 years old

• height >160 cm

• fast weight >65 Kg

• Body Mass Index (BMI) >22.

Exclusion Criteria:

• Diabetes

• vascular diseases

• liver diseases

• renal failure

• cancer

• chronic obstructive pulmonary disease (COPD)

• alcohol, drugs or tobacco addiction

• convulsive diseases

• hypothyroidism

• tuberculosis or chronic debilitating diseases

• use of statins or other lipid lowering drugs

• anticoagulants drugs

• herbal remedies.

• For women 18 to 50 years old, pregnancy should ruled out with a proper test before recruiting and anti conceptive measures must be started in case of active sexual life during all the time of the study and 2 additional weeks.